PHILOGEN S.p.A.

CALENDAR OF CORPORATE EVENTS 2024

Siena (Italy), January 22, 2024 - Philogen S.p.A. (the "**Company"** or "**Philogen**") announces, pursuant to Article 2.6.2 paragraph 1 of the Rules of the Markets organized and managed by Borsa Italiana S.p.A. the calendar of corporate events for the year 2024.

- **March 27, 2024**

Board of Directors to approve the Draft Operating and Consolidated Financial Statements 2023

- **April 29, 2024**

Shareholders' meeting to approve the 2023 financial statements

- **May 7, 2024**

Board of Directors to approve the press release containing a quarterly report with selected information indicative of business performance related to Q1 2024 (*net financial position and progress of NidlegyTM and Fibromun main trials)*

- **September 25, 2024**

Board of Directors to approve the Half-Yearly Financial Report as of June 30, 2024

- **November 7, 2024**

Board of Directors to approve the press release containing a quarterly report with selected information indicative of business performance related to Q3 2024 (*net financial position and progress of NidlegyTM and Fibromun main trials*)

Philogen will promptly notify any changes from the announced dates. The calendar of corporate events is also available on the Company's website www.philogen.com in the "investors/financial-calendar" section

* * *

Philogen Group Description.

Philogen is an Italian-Swiss company active in the biotechnology sector, specializing in the research and development of pharmaceuticals for the treatment of highly lethal diseases. The Group mainly discovers and develops targeted anticancer drugs by exploiting high-affinity ligands for tumor markers (also called tumor antigens). These ligands-human monoclonal antibodies or small organic molecules-are identified using *Antibody Phage Display Libraries* and DNA-Encoded *Chemical Libraries* technologies.

The Group's main therapeutic strategy for the treatment of such diseases is the so-called *tumor targeting.* This approach is based on the use of ligands capable of selectively delivering very potent therapeutic active ingredients (such as, for example, pro-inflammatory cytokines) at the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly developed monoclonal antibody-based ligands that are specific for antigens expressed in tumor-associated blood vessels but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of tumor cells. This approach, so-called *vascular targeting*, is used for most of the projects pursued by the Group.

The Group's goal is to generate, develop, and commercialize innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by leveraging (i) proprietary technologies for the isolation of ligands that react with antigens present in specific diseases, (ii) experience in developing products targeted to the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) the Group's extensive portfolio of patents and intellectual property rights.

Although the Group's drugs are primarily oncology applications, the *targeting* approach is also potentially applicable to other diseases, such as some chronic inflammatory diseases.

* * *

FOR MORE INFORMATION:

Philogen - Investor Relations

IR@philogen.com - Emanuele Puca | *Investor Relator*